Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2025)
Fate Therapeutics (FATE) reported Gains from Investment Securities of -$45000.0 for Q4 2025, up 95.22% quarter-over-quarter from -$942000.0 in Q3 2024.
Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2025) Analysis & Trends
Fate Therapeutics has reported Gains from Investment Securities for 11 years, with the latest figure at -$45000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$45000.0; the trailing twelve-month figure through Dec 2025 stood at -$987000.0 (up 1.69% YoY), and the FY2025 full-year result was -$9000.0, up 99.04% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$45000.0, up from -$942000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $7.1 million in Q4 2021, with the low at -$942000.0 in Q3 2024.
- Historically, Gains from Investment Securities has averaged $1.1 million across 5 years, with a median of $102000.0 in 2021.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities surged 493.77% — and 2024, when it slumped 1419.35%.
- Fate Therapeutics' Gains from Investment Securities stood at $7.1 million in 2021, then slumped by 97.68% to $164000.0 in 2022, then sank by 137.8% to -$62000.0 in 2023, then tumbled by 1419.35% to -$942000.0 in 2024, then jumped by 95.22% to -$45000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$45000.0 (Q4 2025), -$942000.0 (Q3 2024), and -$62000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -45,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Sep 30, 2024 | -942,000.00 |
| Sep 30, 2024 | -942,000.00 |
| Sep 30, 2023 | -62,000.00 |
| Sep 30, 2023 | -62,000.00 |
| Sep 30, 2022 | 164,000.00 |
| Sep 30, 2022 | 164,000.00 |
| Dec 31, 2021 | 7.05 Mn |
| Dec 31, 2021 | 7.05 Mn |
| Jun 30, 2021 | 102,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Mar 31, 2021 | 1.44 Mn |
| Mar 31, 2021 | 1.44 Mn |
| Dec 31, 2020 | 1.19 Mn |
| Dec 31, 2020 | 1.19 Mn |
| Sep 30, 2020 | -127,000.00 |
| Sep 30, 2020 | -127,000.00 |
| Jun 30, 2020 | 418,000.00 |
| Jun 30, 2020 | 418,000.00 |